Goodpasture's syndrome model mouse
Abstract
The present invention provides a non-human model animal of Goodpasture's syndrome that contributes to the treatment of Goodpasture's syndrome where the development of therapy had been delayed due to the lack of adequate disease models, a method for screening a remedy for Goodpasture's syndrome by using the model animal, and a method for diagnosing Goodpasture's syndrome at the early stage. A Goodpasture's syndrome model mouse is constructed by immunizing immunoglobulin Fcgamma receptor IIB knockout mouse with type IV collagen, thereby inducing Goodpasture's syndrome. Moreover, a remedy for Goodpasture's syndrome is screened by administration of test substances to the Goodpasture's syndrome model mouse, followed by evaluating the severity of the expression of Goodpasture's syndrome as an index, such as diffuse alveolar hemorrhage, glomerulonephritis, the appearance of antikidney glomerular basement membrane antibody, and the like.
Claims
exact text as granted — not AI-modified1 - 7 . (canceled)
8 . A method for diagnosing Goodpasture's syndrome at the early stage characterized in that a Fcγ receptor IIB gene is extracted from human test cells and is examined whether there is any deficiency in the function of said gene.Join the waitlist — get patent alerts
Track US2007039062A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.